Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.75 Consensus Price Target from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $9.75.

Several research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a report on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th.

Institutional Trading of Aclaris Therapeutics

Institutional investors have recently made changes to their positions in the company. ProShare Advisors LLC purchased a new position in Aclaris Therapeutics in the second quarter worth approximately $26,000. AXQ Capital LP acquired a new position in shares of Aclaris Therapeutics in the 3rd quarter valued at $27,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Aclaris Therapeutics in the 2nd quarter valued at $28,000. XTX Topco Ltd purchased a new position in shares of Aclaris Therapeutics during the 2nd quarter worth $34,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth about $48,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Price Performance

Shares of Aclaris Therapeutics stock opened at $4.50 on Friday. The stock’s 50 day simple moving average is $2.99 and its 200-day simple moving average is $2.29. The stock has a market cap of $487.58 million, a P/E ratio of -3.26 and a beta of 0.41. Aclaris Therapeutics has a 1-year low of $1.05 and a 1-year high of $4.89.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. The firm had revenue of $3.30 million during the quarter, compared to analysts’ expectations of $1.59 million. Aclaris Therapeutics had a negative return on equity of 39.73% and a negative net margin of 900.01%. As a group, research analysts expect that Aclaris Therapeutics will post -0.82 EPS for the current fiscal year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing novel small?molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non?melanoma skin lesions. Lead programs include ATI?50002, a topical agent in late?stage development for molluscum contagiosum removal; ATI?50003 for common wart resolution; ATI?1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI?450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.